Jpmorgan Chase & CO Oncolytics Biotech Inc Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$1.22 - $2.09 $14,030 - $24,035	11,500 New	11,500 $15,000
Q1 2022 May 11, 2022	SELL	$1.31 - $2.02 $47,467 - $73,194	-36,235 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$1.39 - $2.3 $154,620 - $255,847	-111,238 Reduced 75.43%	36,235 $50,000
Q3 2021 Nov 12, 2021	BUY	$1.93 - $2.77 $284,622 - $408,500	147,473 New	147,473 $900,000

1.18M

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $49.2M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.